Karyopharm Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Significant progress reported in myelofibrosis and endometrial cancer programs, with phase III SENTRY data showing strong efficacy and survival signals in myelofibrosis and EC-042 readout expected mid-year. Regulatory and commercial strategies are in place, with cash runway into late Q3.
-
The phase III SENTRY trial showed selinexor plus ruxolitinib significantly improved spleen volume reduction and provided an early survival benefit in JAK inhibitor-naive myelofibrosis patients, with manageable safety and consistent efficacy across subgroups. SVR35 correlated with survival, and the combination may address real-world dosing challenges.
-
The meeting confirmed a quorum and approved all five proposals, including director elections, plan amendments, executive compensation, and auditor ratification. No questions were raised by shareholders, and final voting results will be filed in a Form 8-K.
-
Phase III SENTRY data for selinexor plus ruxolitinib in myelofibrosis show rapid, deep responses and a strong early survival signal, with full results to be presented at ASCO. Regulatory and guideline engagement is progressing, and the endometrial cancer program targets a high unmet need subgroup.
-
Selinexor is advancing in myelofibrosis and endometrial cancer, with strong SENTRY trial results showing improved spleen volume reduction and early overall survival benefit. Regulatory flexibility and a robust commercial strategy position the drug for significant market impact.
-
Q1 2026 saw strong revenue growth and key clinical milestones, including positive SENTRY phase III results in myelofibrosis and completed enrollment in the XPORT-EC-042 endometrial cancer trial. Liquidity was strengthened with $50 million in new financing, supporting operations into late Q3 2026.
-
The phase III SENTRY trial showed Selinexor plus Ruxolitinib nearly doubled spleen response rates and provided a significant overall survival benefit in JAK inhibitor-naive Myelofibrosis, with a manageable safety profile and evidence of disease modification.
-
A virtual special meeting was held to vote on increasing authorized shares and the potential adjournment for further proxy solicitation. Both proposals passed, with final results to be filed in a Form 8-K. No questions were raised by stockholders.
Fiscal Year 2025
-
Revenue grew modestly in 2025, with XPOVIO sales up and cost reductions improving operating loss. Pivotal phase 3 data in myelofibrosis is expected in March, with a strong commercial focus on this opportunity and a cash runway into Q2 2026.
-
Selinexor plus ruxolitinib shows strong efficacy and manageable safety in myelofibrosis, with phase III SENTRY results expected in March. The combination could address significant unmet needs, offering a potential new frontline standard and a major commercial opportunity.
-
Selinexor, an oral Exportin-1 inhibitor, is expanding its reach in multiple myeloma and advancing in myelofibrosis and endometrial cancer, with pivotal phase III data expected in 2024 and 2026. Market potential is strong, supported by recent financial restructuring and robust clinical results.
-
Q3 2025 revenue grew 13% year-over-year, driven by XPOVIO and milestone revenues. SENTRY Phase III trial in myelofibrosis completed enrollment, with top-line data expected March 2026. Financial flexibility was strengthened, supporting operations into Q2 2026.
-
Q2 2025 saw solid commercial performance with XPOVIO net product revenue up 6% year-over-year and royalty revenue up 28%. Liquidity remains a concern due to an October debt maturity, but pivotal phase III trial readouts in myelofibrosis and endometrial cancer are on track for 2026.
-
Two late-stage trials in myelofibrosis and endometrial cancer are nearing key data readouts, with Selinexor showing strong efficacy and durability, especially in biomarker-defined populations. Commercial infrastructure is ready for rapid launches pending positive results.
-
The meeting covered director elections, equity plan amendments, executive compensation, and auditor ratification, all of which were approved. Management addressed shareholder concerns about cash runway and value creation, emphasizing a focus on late-stage pipeline advancement.
-
Selinexor demand is growing, with strong positioning in multiple myeloma and promising phase III trials in myelofibrosis and endometrial cancer. Regulatory and clinical endpoint innovations, improved safety, and operational discipline support anticipated transformational readouts in the next two years.
-
Q1 2025 revenue declined due to atypical product returns, but demand for XPOVIO grew 5% year-over-year. The phase 3 Sentry trial in myelofibrosis passed futility analysis and is nearing full enrollment, with top-line data expected by early 2026. Guidance now tracks to the lower end, and cash runway extends into early Q4 2025.
Fiscal Year 2024
-
Solid 2024 results with XPOVIO revenue growth and cost reductions, while advancing pivotal phase III trials in myelofibrosis and endometrial cancer. 2025 guidance projects stable revenue and lower expenses, with a focus on clinical milestones and extending cash runway.
-
Recent clinical data show strong efficacy and durability for selinexor-based combinations in myelofibrosis and multiple myeloma, with evolving trial endpoints and manageable safety at lower doses. Key Phase 3 milestones are on track for 2025.
-
Q3 2024 saw continued U.S. revenue growth, strong international expansion, and progress in three pivotal phase III trials. Updated endpoints and robust clinical data in myelofibrosis and endometrial cancer support $1B+ peak revenue opportunities in each.
-
The SENTRY phase III trial in myelofibrosis has updated its co-primary endpoints to SVR35 and Absolute TSS, enhancing statistical power and aligning with FDA guidance. This change is supported by strong phase I data and is expected to improve patient outcome assessment.
-
Focused on XPO1 inhibition, the pipeline aims to transform care in myelofibrosis, endometrial cancer, and multiple myeloma, with strong clinical data and a robust financial position. Key phase III data readouts are expected from H1 2025 through early 2026.
-
Q2 2024 revenue rose to $42.8M, with XPOVIO net product revenue up 8% sequentially and guidance raised for the year. Strong clinical progress in myelofibrosis, endometrial cancer, and multiple myeloma supports a robust late-stage pipeline, while cost controls extend cash runway into early 2026.
-
Phase III data highlight selinexor’s strong efficacy in p53 wild-type endometrial cancer, especially in pMMR patients, with a new trial using a lower dose and improved safety. Myelofibrosis and multiple myeloma programs show promising results, with key readouts expected through 2025.